Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: a case report

[1] Gallo LA(2015)Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences Diabetes Vasc Dis Res 12 78-89

[2] Wright EM(2014)Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria Diabetes Res Clin Pract 103 373-381

[3] Vallon V(2016)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128

[4] Geerlings S(2013)Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 129 587-597

[5] Fonseca V(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657

[6] Castro-Diaz D(2017)SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system Diabetologia 60 1385-1389

[7] List J(2016)American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis Endocr Pract 22 753-762

[8] Parikh S(2014)Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial Diabetes Care 37 1480-1483

[9] Zinman B(2015)Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication Am J Emerg Med 33 e3-604.e4

[10] Christoph W(2017)Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives Diabetes Metab Res Rev 33 1-9

[1] Gallo LA(2015)Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences Diabetes Vasc Dis Res 12 78-89

[2] Wright EM(2014)Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria Diabetes Res Clin Pract 103 373-381

[3] Vallon V(2016)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128

[4] Geerlings S(2013)Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 129 587-597

[5] Fonseca V(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657

[6] Castro-Diaz D(2017)SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system Diabetologia 60 1385-1389

[7] List J(2016)American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis Endocr Pract 22 753-762

[8] Parikh S(2014)Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial Diabetes Care 37 1480-1483

[9] Zinman B(2015)Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication Am J Emerg Med 33 e3-604.e4

[10] Christoph W(2017)Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives Diabetes Metab Res Rev 33 1-9